Compare Hubbell (HUBB) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hubbell vs Travere Therapeutics Inc. Common Stock — how do they compare? Hubbell trades at $469.9 (market cap $25.25B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Hubbell is far larger — about 5.2× Travere Therapeutics Inc. Common Stock's market cap, and Hubbell pays a 1.19% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hubbell for 6 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| HUBB | TVTX | |
|---|---|---|
Market Cap | $25.25B | $4.88B |
Volume | 443,319 | 1,668,577 |
Sector | Industrials | Health |
52-Week High | $557.85 | $67.52 |
52-Week Low | $407.36 | $26.79 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $30.41B | $5.01B |
Dividend Yield | 1.19% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hubbell Incorporated (HUBB) trades at $477.93, up 0.82% with a neutral technical signal. The stock shows strong fundamentals with consistent earnings beats (Q4 2025: $4.73 vs. $4.71 expected, Q1 2026: $3.93 vs. $3.87, Q2 2026: $5.52 vs. $5.39) and robust profitability (net margin 14.49%, ROE 24.34%). Recent news highlights grid modernization opportunities and institutional buying interest from Bank of America and BNY Mellon.
Hubbell presents a favorable outlook with analyst consensus price target of $560.50 (17% upside) and strong institutional support. Key risks include integration challenges from recent acquisitions and dependence on utility spending cycles. The Q3 2026 earnings report on October 27 will be crucial for validating growth trajectory amid electrification demand.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hubbell
Hubbell manufactures electrical and utility products used in transmission, distribution, and electrical infrastructure. Its portfolio includes components and systems for utilities, data centers, industrial facilities, and buildings.
Read more on HUBB →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
